Table 2.
Prostate cancer risk by subgroups
| Full cohort | Genotyped men | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NonPrCa* | PrCa | PrCa-risk | NonPrCa | PrCa | PrCa-risk | |||||||
| Serum selenium(μg/l) | N | % | N | % | RR** | 95% CI*** | N | % | N | % | RR | 95% CI |
| ≤70 | 675 | (36.7) | 84 | (40.4) | Ref | - | 295 | (33.6) | 48 | (38.1) | Ref | - |
| 70.1-81.0 | 588 | (32.0) | 65 | (31.2) | 0.89 | (0.65 - 1.24) | 299 | (34.0) | 46 | (35.7) | 0.93 | (0.62 - 1.4) |
| 81+ | 574 | (31.2) | 59 | (28.4) | 0.83 | (0.60 - 1.16) | 285 | (32.4) | 33 | (26.2) | 0.72 | (0.46 - 1.12) |
| Erythrocyte sedimentation rate, ESR(mm/h) | ||||||||||||
| ≤4.0 | 704 | (38.3) | 84 | (40.4) | Ref | - | 348 | (39.6) | 51 | (40.5) | Ref | - |
| 4.1-8.0 | 587 | (32.0) | 67 | (32.2) | 0.97 | (0.70 - 1.33) | 297 | (33.8) | 38 | (30.2) | 0.89 | (0.58 - 1.35) |
| 8+ | 545 | (29.7) | 57 | (27.4) | 0.88 | (0.63 - 1.23) | 234 | (26.6) | 37 | (29.4) | 1.07 | (0.7 - 1.62) |
| Total serum cholesterol(mmol/l) | ||||||||||||
| ≤6.24 | 560 | (30.5) | 76 | (36.5) | Ref | - | 288 | (32.8) | 48 | (38.1) | Ref | - |
| 6.25-7.27 | 624 | (34.0) | 64 | (30.8) | 0.77 | (0.55 - 1.07) | 295 | (33.6) | 40 | (31.7) | 0.82 | (0.54 - 1.25) |
| 7.27+ | 653 | (35.5) | 68 | (32.7) | 0.78 | (0.56 - 1.08) | 296 | (33.7) | 38 | (30.2) | 0.78 | (0.51- 1.19) |
| BMI(kg/m2) | ||||||||||||
| ≤23.4 | 605 | (32.9) | 61 | (29.3) | Ref | - | 296 | (33.7) | 39 | (31.0) | Ref | - |
| 23.5-26.0 | 567 | (30.9) | 78 | (37.5) | 1.34 | (0.96 - 1.87) | 285 | (32.4) | 50 | (39.7) | 1.31 | (0.86 - 1.99) |
| 26+ | 665 | (36.2) | 69 | (33.2) | 1.03 | (0.73 - 1.46) | 298 | (33.9) | 37 | (29.4) | 0.96 | (0.61 - 1.5) |
| Smoking | ||||||||||||
| non-smoker | 449 | (24.4) | 69 | (33.2) | Ref | - | 258 | (29.4) | 45 | (35.7) | Ref | - |
| smoker | 961 | (52.3) | 86 | (41.3) | 0.6 | (0.44 - 0.83) | 394 | (44.8) | 47 | (37.3) | 0.70 | (0.46 - 1.05) |
| ex-smoker | 427 | (23.2) | 53 | (25.5) | 0.82 | (0.58 - 1.18) | 227 | (25.8) | 34 | (27.0) | 0.87 | (0.56 - 1.36) |
Unadjusted relative risk (RR) of prostate cancer (PrCa) for baseline tertiles of selenium with 95% confidence intervals (CI), the two selenium level modifying factors ESR, total cholesterol, BMI and for smoking status in the full cohort and in the genotyped men. The lowest tertiles and the non-smokers were used as references.
* Prostate cancer
** Relative risk
*** Confidence interval